Skip to main content
Sign In

Ongoing Studies

The studies listed below are actively recruiting volunteers. Check the tab for additional details and eligibiligy criteria.

The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Trial

GRADE is a nation-wide study funded by the National Institutes of Health.

Iron Reduction by Phlebotomy for the Prevention and Treatment of Type 2 Diabetes

IRON is sponsored by the NIH and the University of Utah.


SUSTAIN is a long-term, randomized, double blinded, placebo-controlled, multinational, multi-centre trial to ecaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes sponsored by Novo Nordisk Pharmaceuticals, Inc.

Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results

LEADER is a long-term, multicentre, international, randomized, double-blind, placebo-controlled trial to determine liraglutide effects on cardiovascular events and is sponsored by Novo Dordisk Pharmaceuticals, Inc.

​The Pfizer B1261007 study is a phase 1, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaulate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist in adults with Type 2 Diabetes and overt nephropathy.